Candel Therapeutics, Inc. (NASDAQ:CADL) on Wednesday revealed final survival data from a phase 2a trial of CAN-2409 in ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) is expected to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Lake Street Capital in a research report issued on Monday ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

"Sun Pharma")) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

Checkpoint Therapeutics recently gained approval for cosibelimab, a PD-L1 inhibitor for advanced cSCC, but faces stiff competition and financial challenges. CKPT's pipeline includes cosibelimab ...

About Checkpoint Therapeutics, Inc. Checkpoint is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments ...